Cargando…
IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Retraction]
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416483/ https://www.ncbi.nlm.nih.gov/pubmed/36033902 http://dx.doi.org/10.2147/OTT.S386447 |
Ejemplares similares
-
IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells
por: Li, Yu, et al.
Publicado: (2020) -
IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Corrigendum]
Publicado: (2020) -
Retraction: Fingolimod inhibits proliferation and epithelial- mesenchymal transition in sacral chordoma by inactivating IL-6/STAT3 signaling
Publicado: (2020) -
Hypoxia-Induced Aquaporin-3 Changes Hepatocellular Carcinoma Cell Sensitivity to Sorafenib by Activating the PI3K/Akt Signaling Pathway [Retraction]
Publicado: (2021) -
miR-222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma
por: Liu, Kai, et al.
Publicado: (2021)